Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia

International Journal of Laboratory Hematology

Volumn 31, Issue 1, 2009, Pages 97-105

  Jilani, I ^a   Wei, C ^b   Bekele, B N ^b   Zhang, Z J ^a   Keating, M ^b   Wierda, W ^b   Ferrajoli, A ^b   Estrov, Z ^b   Kantarjian, H ^b   O'Brien, S M ^b   Giles, F J ^b   Albitar, M ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CD138; CLL; IgVH; Prognosis; Survival; Syndecan

Indexed keywords

BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; SYNDECAN 1;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; EPITHELIUM CELL; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MUTATION; MYELOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SOLUBILITY; SYNDECAN-1; TUMOR MARKERS, BIOLOGICAL;

EID: 58449133477     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2007.01010.x     Document Type: Article

References (45)

1. Bernfield M., Kokenyesi R., Kato M., Reizes O., Fitzgerald M., Lincecum J. Zako M. (1992) Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annual Review of Cell Biology 8, 365 393.
2. Bernfield M., Gotte M., Park P.W., Hinkes M.T., Spring J., Gallo R.L. Lose E.J. (1999) Functions of cell surface heparan sulfate proteoglycans. Annual Review of Chemistry Biol 68, 729 777.
3. Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F., Thomas M., Tchernia G., Jacquillat C., Boivin P., Lesty C., Duault M.T., Monconduit M., Belabbes S. Gremy F. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48, 198 206.
4. Carbone A., Gloghini A., Gattei V., Degan M., Improta S., Aldinucci D., Canzonieri V., Perin T., Volpe R., Gaidano G., Zagonel V. Pinto A. (1997) Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. Blood 89, 3787 3794.
5. Carbone A., Gloghini A., Larocca L.M., Capello D., Pierconti F., Canzonieri V., Tirelli U., Dalla-Favera R. Gaidano G. (2001) Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 97, 744 751.
6. Chiorazzi N., Rai K.R. Ferrarini M. (2005) Chronic lymphocytic leukemia. New England Journal of Medicine 352, 804 815.
7. Cox D.R. (1972) Regression models and life tables. Journal of Royal Statistical Society 34, 187 220.
8. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., Marcé S., López-Guillermo A., Campo E. Montserrat E. (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. New England Journal of Medicine 348, 1764 1775.
9. Derksen P.W., Keehnen R.M., Evers L.M., van Oers M.H., Spaargaren M. Pals S.T. (2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99, 1405 1410.
10. Ding K., Lopez-Burks M., Sanchez-Duran J.A., Korc M. Lander A.D. (2005) Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. Journal of Cell Biology 171, 729 738.
11. Fitzgerald M.L., Wang Z., Park P.W., Murphy G. Bernfield M. (2000) Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. Journal of Cell Biology 148, 811 824.
12. Hallek M., Wanders L., Ostwald M., Busch R., Senekowitsch R., Stern S., Schick H.D., Kuhn-Hallek I. Emmerich B. (1996) Serum beta (2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leukemia & Lymphoma 22, 439 447.
13. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G. Stevenson F.K. (1999) Unmutated Ig V (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848 1854.
14. Inki P., Joensuu H., Grenman R., Klemi P. Jalkanen M. (1994) Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. British Journal of Cancer 70, 319 323.
15. Joensuu H., Anttonen A., Eriksson M., Mäkitaro R., Alfthan H., Kinnula V. Leppä S. (2002) Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Research 62, 5210 5217.
16. Juuti A., Nordling S., Lundin J., Louhimo J. Haglund C. (2005) Syndecan-1 expression - a novel prognostic marker in pancreatic cancer. Oncology 68, 97 106.
17. Kaplan E.L. Meier P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association 53, 457 481.
18. Kim C.W., Goldberger O.A., Gallo R.L. Bernfield M. (1994) Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Molecular Biology of the Cell 5, 797 805.
19. Koller C., Bekele B.N., Zhou X., Park C., Estrov Z., O'Brien S., Keating M., Jilani I., Giles F., Kantarjian H. Albitar M. (2006) Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood 108, 1001 1006.
20. Krober A., Bloehdorn J., Hafner S., Bühler A., Seiler T., Kienle D., Winkler D., Bangerter M., Schlenk R., Benner A., Lichter P., Döhner H. Stilgenbauer S. (2006) Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. Journal of Clinical Oncology 24, 969 975.
21. Kumar-Singh S., Jacobs W., Dhaene K., Weyn B., Bogers J., Weyler J. Van Marck E. (1998) Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. Journal of Pathology 186, 300 305.
22. Lalor P.A., Nossal G.J., Sanderson R.D. McHeyzer-Williams M.G. (1992) Functional and molecular characterization of single, (4-hydroxy-3-nitrophenyl) acetyl (NP)-specific, IgG1+ B cells from antibody-secreting and memory B cell pathways in the C57BL/6 immune response to NP. European Journal of Immunology 22, 3001 3011.
23. Leivonen M., Lundin J., Nordling S., von Boguslawski K. Haglund C. (2004) Prognostic value of syndecan-1 expression in breast cancer. Oncology 67, 11 18.
24. Lovell R., Dunn J.A., Begum G., Barth N., Plant T., Moss P., Drayson M. Pratt G. (2005) Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. British Journal of Haematology 130, 542 548.
25. Molica S., Levato D., Cascavilla N., Levato L. Musto P. (1999) Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. European Journal of Haematology 62, 117 122.
26. Molica S., Vitelli G., Mirabelli R., Digiesu G., Giannarelli D., Cuneo A., Ribatti D. Vacca A. (2006) Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia: correlation with the extent of angiogenesis and disease-progression risk in early disease. Leukemia & Lymphoma 47, 1034 1040.
27. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.D., Mantel N., McPherson K., Peto J. Smith P.G. (1997) Design and analysis of randomized clinical trials requiring prolonged observation of each: II, analysis and examples. British Journal of Cancer 35, 1 39.
28. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N. Pasternack B.S. (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46, 219 234.
29. Redaelli A., Laskin B.L., Stephens J.M., Botteman M.F. Pashos C.L. (2004) The clinical and epidemiological burden of chronic lymphocytic leukaemia. European Journal of Cancer Care 13, 279 287.
30. Saka B., Aktan M., Sami U., Oner D., Sanem O. Dincol G. (2006) Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia. Clinical and Laboratory Haematology 28, 30 35.
31. Sanderson R.D., Lalor P. Bernfield M. (1989) B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regulation 1, 27 35.
32. Sebestyen A., Kovalszky I., Mihalik R., Gallia M., Bocsil J., Laszlo E., Benedek S., Sreter L. Kopper L. (1997) Expression of syndecan-1 in human B cell chronic lymphocytic leukaemia. European Journal of Cancer 33, 2273 2277.
33. Seidel C., Sundan A., Hjorth M., Turreson I., Dahl I.M.S., Abildgaard N., Waage A. Borset M. (2000) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95, 388 392.
34. Shanafelt T.D., Geyer S.M. Kay N.E. (2004) Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 103, 1202 1210.
35. Snedecor G.W. Cochran W.G. (1980) Statistical Methods, 7th edn. Iowa Stat University Press, Ames Iowa.
36. Sutcliffe M., Oscier D. Wright D.H. (2000) SYNDECAN-1 (CD138) expression in human non-Hodgkin's lymphomas. British Journal of Haematology 110, 239 240.
37. Thall P.F. Estey E.H. (2001) Graphical methods for evaluating covariae effects in the Cox model. In : Handbook of Statistics in Clinical Oncology (ed. J. Crowley pp. 411 432. Marcel Dekker New York, NY.
38. Thermeau T.M. Grambsch P.M. (2000) Modeling Survival Data. Springer New York, NY.
39. Tobin G., Soderberg O., Thunberg U. Rosenquist R. (2004) V(H)3-21 gene usage in chronic lymphocytic leukemia - characterization of a new subgroup with distinct molecular features and poor survival. Leukemia & Lymphoma 45, 221 228.
40. Wang Z., Gotte M., Bernfield M. Reizes O. (2005) Constitutive and accelerated shedding of murine syndecan-1 is mediated by cleavage of its core protein at a specific juxtamembrane site. Biochemistry 44, 12355 12361.
41. Wijdenes J., Vooijs W.C., Clement C., Post J., Morard F., Vita N., Laurent P., Sun R.X., Klien B. Dore J.M. (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. British Journal of Haematology 94, 318 323.
42. Witzig T.E., Kimlinger T., Stenson M. Therneau T. (1998) Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leukemia & Lymphoma 31, 167 175.
43. Wolowiec D., Dybko J., Wrobel T., Urbaniak-Kujda D., Jazwiec B., Tomaszewska-Toporska B., Kapelko-Slowik K., Potoczek S. Kulizckowski K. (2006) Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators of Inflammation 2006, 42394.
44. Woods A. (2001) Syndecans: transmembrane modulators of adhesion and matrix assembly. The Journal of Clinical Investigation 107, 935 941.
45. Zhang Z., Coomans C. David G. (2001) Membrane heparan sulfate proteoglycan-supported FGF2-FGFR1 signaling: evidence in support of the "cooperative end structures" model. Journal of Biological Chemistry 276, 41921 41929.